ECU
TEVA icon

Eisler Capital (US)’s Teva Pharmaceuticals TEVA Stock Holding History

Eisler Capital (US)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-253,497
Closed -$4.12M – 663
2024
Q2 		$4.12M Buy
+253,497
New +$3.9M 0.07% 233

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Eisler Capital (US)'s TEVA Position: Q3 2024 in Review

Eisler Capital (US) sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 253,497 shares — an estimated $4.12M sold.

Eisler Capital (US) first reported a position in TEVA in Q2 2024 and held it in 1 quarter. The position peaked at $4.12M in Q2 2024. 543 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Eisler Capital (US) reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Eisler Capital (US) sold 253,497 Teva Pharmaceuticals shares in Q3 2024, an estimated $4.12M.
  • Eisler Capital (US) first reported a position in Teva Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Eisler Capital (US)'s Teva Pharmaceuticals position peaked at $4.12M in Q2 2024.
  • 543 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Eisler Capital (US)'s 13F filing for Q3 2024, filed 14 Nov 2024.